These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 29529042

  • 21. Systemic Inflammatory Protein Profiles Distinguish Irritable Bowel Syndrome (IBS) and Ulcerative Colitis, Irrespective of Inflammation or IBS-Like Symptoms.
    Moraes L, Magnusson MK, Mavroudis G, Polster A, Jonefjäll B, Törnblom H, Sundin J, Simrén M, Strid H, Öhman L.
    Inflamm Bowel Dis; 2020 May 12; 26(6):874-884. PubMed ID: 31901089
    [Abstract] [Full Text] [Related]

  • 22. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation.
    Vivinus-Nébot M, Frin-Mathy G, Bzioueche H, Dainese R, Bernard G, Anty R, Filippi J, Saint-Paul MC, Tulic MK, Verhasselt V, Hébuterne X, Piche T.
    Gut; 2014 May 12; 63(5):744-52. PubMed ID: 23878165
    [Abstract] [Full Text] [Related]

  • 23. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity.
    Gecse K, Róka R, Ferrier L, Leveque M, Eutamene H, Cartier C, Ait-Belgnaoui A, Rosztóczy A, Izbéki F, Fioramonti J, Wittmann T, Bueno L.
    Gut; 2008 May 12; 57(5):591-9. PubMed ID: 18194983
    [Abstract] [Full Text] [Related]

  • 24. Alterations in mucosal neuropeptides in patients with irritable bowel syndrome and ulcerative colitis in remission: a role in pain symptom generation?
    Keszthelyi D, Troost FJ, Jonkers DM, Helyes Z, Hamer HM, Ludidi S, Vanhoutvin S, Venema K, Dekker J, Szolcsányi J, Masclee AA.
    Eur J Pain; 2013 Oct 12; 17(9):1299-306. PubMed ID: 23529955
    [Abstract] [Full Text] [Related]

  • 25. Protease activated receptor 2: a new target for IBS treatment.
    Bueno L.
    Eur Rev Med Pharmacol Sci; 2008 Aug 12; 12 Suppl 1():95-102. PubMed ID: 18924448
    [Abstract] [Full Text] [Related]

  • 26. Patients with longstanding ulcerative colitis in remission do not have more irritable bowel syndrome-like symptoms than controls.
    Lundgren D, Rutegård J, Eklöf V, Palmqvist R, Karling P.
    BMC Gastroenterol; 2016 Nov 24; 16(1):139. PubMed ID: 27881072
    [Abstract] [Full Text] [Related]

  • 27. CRF induces intestinal epithelial barrier injury via the release of mast cell proteases and TNF-α.
    Overman EL, Rivier JE, Moeser AJ.
    PLoS One; 2012 Nov 24; 7(6):e39935. PubMed ID: 22768175
    [Abstract] [Full Text] [Related]

  • 28. Activity of protease-activated receptors in the human submucous plexus.
    Mueller K, Michel K, Krueger D, Demir IE, Ceyhan GO, Zeller F, Kreis ME, Schemann M.
    Gastroenterology; 2011 Dec 24; 141(6):2088-2097.e1. PubMed ID: 21875497
    [Abstract] [Full Text] [Related]

  • 29. S100A expression and interleukin-10 polymorphisms are associated with ulcerative colitis and diarrhea predominant irritable bowel syndrome.
    Shiotani A, Kusunoki H, Kimura Y, Ishii M, Imamura H, Tarumi K, Manabe N, Kamada T, Hata J, Haruma K.
    Dig Dis Sci; 2013 Aug 24; 58(8):2314-23. PubMed ID: 23595519
    [Abstract] [Full Text] [Related]

  • 30. Histamine Receptor H1-Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome.
    Wouters MM, Balemans D, Van Wanrooy S, Dooley J, Cibert-Goton V, Alpizar YA, Valdez-Morales EE, Nasser Y, Van Veldhoven PP, Vanbrabant W, Van der Merwe S, Mols R, Ghesquière B, Cirillo C, Kortekaas I, Carmeliet P, Peetermans WE, Vermeire S, Rutgeerts P, Augustijns P, Hellings PW, Belmans A, Vanner S, Bulmer DC, Talavera K, Vanden Berghe P, Liston A, Boeckxstaens GE.
    Gastroenterology; 2016 Apr 24; 150(4):875-87.e9. PubMed ID: 26752109
    [Abstract] [Full Text] [Related]

  • 31. Reduced Responses of Submucous Neurons from Irritable Bowel Syndrome Patients to a Cocktail Containing Histamine, Serotonin, TNFα, and Tryptase (IBS-Cocktail).
    Ostertag D, Buhner S, Michel K, Pehl C, Kurjak M, Götzberger M, Schulte-Frohlinde E, Frieling T, Enck P, Phillip J, Schemann M.
    Front Neurosci; 2015 Apr 24; 9():465. PubMed ID: 26733780
    [Abstract] [Full Text] [Related]

  • 32. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms.
    Cremon C, Gargano L, Morselli-Labate AM, Santini D, Cogliandro RF, De Giorgio R, Stanghellini V, Corinaldesi R, Barbara G.
    Am J Gastroenterol; 2009 Feb 24; 104(2):392-400. PubMed ID: 19174797
    [Abstract] [Full Text] [Related]

  • 33. Multigene analysis can discriminate between ulcerative colitis, Crohn's disease, and irritable bowel syndrome.
    von Stein P, Lofberg R, Kuznetsov NV, Gielen AW, Persson JO, Sundberg R, Hellstrom K, Eriksson A, Befrits R, Ost A, von Stein OD.
    Gastroenterology; 2008 Jun 24; 134(7):1869-81; quiz 2153-4. PubMed ID: 18466904
    [Abstract] [Full Text] [Related]

  • 34. Clinical and subclinical intestinal inflammation assessed by the mucosal patch technique: studies of mucosal neutrophil and eosinophil activation in inflammatory bowel diseases and irritable bowel syndrome.
    Kristjánsson G, Venge P, Wanders A, Lööf L, Hällgren R.
    Gut; 2004 Dec 24; 53(12):1806-12. PubMed ID: 15542519
    [Abstract] [Full Text] [Related]

  • 35. Biopsy samples from patients with irritable bowel syndrome, but not from those with mastocytosis or unspecific gastrointestinal complaints reveal unique nerve activation in all gut regions independent of mast cell density, histamine content or specific gastrointestinal symptoms.
    Vignali S, Buhner S, Greiter W, Daniel H, Frieling T, Schemann M, Annahazi A.
    Front Neurosci; 2024 Dec 24; 18():1291554. PubMed ID: 39015376
    [Abstract] [Full Text] [Related]

  • 36. Colonic mucosal immune activity in irritable bowel syndrome: comparison with healthy controls and patients with ulcerative colitis.
    Ahn JY, Lee KH, Choi CH, Kim JW, Lee HW, Kim JW, Kim MK, Kwon GY, Han S, Kim SE, Kim SM, Chang SK.
    Dig Dis Sci; 2014 May 24; 59(5):1001-11. PubMed ID: 24282051
    [Abstract] [Full Text] [Related]

  • 37. Trypsinogen IV, serotonin transporter transcript levels and serotonin content are increased in small intestine of irritable bowel syndrome patients.
    Kerckhoffs AP, Ter Linde JJ, Akkermans LM, Samsom M.
    Neurogastroenterol Motil; 2008 Aug 24; 20(8):900-7. PubMed ID: 18363639
    [Abstract] [Full Text] [Related]

  • 38. Nerve growth factor content is increased in the rectal mucosa of children with diarrhea-predominant irritable bowel syndrome.
    Willot S, Gauthier C, Patey N, Faure C.
    Neurogastroenterol Motil; 2012 Aug 24; 24(8):734-9, e347. PubMed ID: 22625872
    [Abstract] [Full Text] [Related]

  • 39. Interferon-γ is increased in the gut of patients with irritable bowel syndrome and modulates serotonin metabolism.
    Barbaro MR, Di Sabatino A, Cremon C, Giuffrida P, Fiorentino M, Altimari A, Bellacosa L, Stanghellini V, Barbara G.
    Am J Physiol Gastrointest Liver Physiol; 2016 Mar 15; 310(6):G439-47. PubMed ID: 26744473
    [Abstract] [Full Text] [Related]

  • 40. Intracolonic infusion of fecal supernatants from ulcerative colitis patients triggers altered permeability and inflammation in mice: role of cathepsin G and protease-activated receptor-4.
    Dabek M, Ferrier L, Annahazi A, Bézirard V, Polizzi A, Cartier C, Leveque M, Roka R, Wittmann T, Theodorou V, Bueno L.
    Inflamm Bowel Dis; 2011 Jun 15; 17(6):1409-14. PubMed ID: 21560201
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.